Skip to content
    Clinical Trials

    Phase III KRAS and MAPK Inhibitors Challenge Chemotherapy Standard in First-Line Metastatic PDAC

    Dempke et alFuture Oncol

    Phase III KRAS and MAPK Inhibitors Challenge Chemotherapy Standard in First-Line Metastatic PDAC
    Metastatic pancreatic ductal adenocarcinoma (PDAC) accounts for more than 5% of all cancer deaths worldwide, with 5-year survival rates remaining under 5% in the metastatic setting. Combination chemotherapy regimens currently serve as the standard of care. Although KRAS oncogenes are altered in over 90% of PDAC cases, they were historically regarded as undruggable.
    A new wave of highly specific inhibitors targeting KRAS and downstream pathways has entered phase III clinical evaluation for first-line metastatic PDAC. These agents include atebimetinib (a MEK inhibitor), daraxonrasib (a tri-complex pan-KRAS inhibitor), zoldonrasib (a tri-complex KRAS G12D inhibitor), INCB161734 (a non-covalent ON/OFF KRAS G12D inhibitor), HRS-4642 (a liposomal G12D inhibitor), and setidegrasib (a G12D degrader).
    Five ongoing phase III trials—RASolute-305 (zoldonrasib), DAWN-303 (INCB161734), MAPKeeper-301 (atebimetinib), along with trials for HRS-4642 and setidegrasib—are comparing chemotherapy plus inhibitor against chemotherapy alone. In contrast, the three-arm randomized RASolute-303 trial features a daraxonrasib monotherapy arm alongside combination regimens. Preliminary clinical outcomes for certain compounds have numerically exceeded historical chemotherapy benchmarks, raising the possibility that frontline treatment strategies may eventually eliminate the need for a chemotherapy backbone.

    Key Takeaways

    • Early clinical outcomes for select novel KRAS and MAPK targeted compounds have numerically exceeded historical benchmarks achieved with standard combination chemotherapy in metastatic pancreatic ductal adenocarcinoma.
    • Six targeted inhibitors—atebimetinib, daraxonrasib, zoldonrasib, INCB161734, HRS-4642, and setidegrasib—are undergoing phase III evaluation in frontline metastatic PDAC, addressing a disease with >90% KRAS addiction and <5% 5-year survival.
    • Phase III trial strategies include five combination studies comparing chemotherapy plus inhibitor versus chemotherapy alone (RASolute-305, DAWN-303, MAPKeeper-301, HRS-4642, and setidegrasib), while the three-arm RASolute-303 trial is evaluating daraxonrasib monotherapy to test chemo-free treatment approaches.